Learning from COVID-19: How drug hunters can prepare for the next pandemic
Over 3 years, the SARS-CoV-2 pandemic killed nearly 7 million people and infected more
than 767 million globally. During this time, our very small company was able to contribute to …
than 767 million globally. During this time, our very small company was able to contribute to …
[HTML][HTML] C5aR1 signaling triggers lung immunopathology in COVID-19 through neutrophil extracellular traps
Patients with severe COVID-19 develop acute respiratory distress syndrome (ARDS) that
may progress to cytokine storm syndrome, organ dysfunction, and death. Considering that …
may progress to cytokine storm syndrome, organ dysfunction, and death. Considering that …
The interference between SARS-COV-2 and Alzheimer's disease: Potential immunological and neurobiological crosstalk from a kinase perspective reveals a delayed …
HM Mansour - Ageing Research Reviews, 2024 - Elsevier
Abstract Coronavirus disease 2019 (COVID-19) has infected over 700 million people, with
up to 30% developing neurological manifestations, including dementias. However, there is a …
up to 30% developing neurological manifestations, including dementias. However, there is a …
Discovery of PLpro and Mpro Inhibitors for SARS-CoV-2
There are very few small-molecule antivirals for SARS-CoV-2 that are either currently
approved (or emergency authorized) in the US or globally, including remdesivir …
approved (or emergency authorized) in the US or globally, including remdesivir …
Unraveling antiviral efficacy of multifunctional immunomodulatory triterpenoids against SARS‐COV‐2 targeting main protease and papain‐like protease
S Choudhary, S Nehul, A Singh, PK Panda… - IUBMB …, 2024 - Wiley Online Library
Abstract The coronavirus disease 2019 (COVID‐19) pandemic, caused by severe acute
respiratory syndrome coronavirus 2 (SARS‐CoV‐2) may be over, but its variants continue to …
respiratory syndrome coronavirus 2 (SARS‐CoV‐2) may be over, but its variants continue to …
Growth hormone–releasing hormone receptor antagonist MIA-602 attenuates cardiopulmonary injury induced by BSL-2 rVSV-SARS-CoV-2 in hACE2 mice
JM Condor Capcha, A Kamiar… - Proceedings of the …, 2023 - National Acad Sciences
COVID-19 pneumonia causes acute lung injury and acute respiratory distress syndrome
(ALI/ARDS) characterized by early pulmonary endothelial and epithelial injuries with altered …
(ALI/ARDS) characterized by early pulmonary endothelial and epithelial injuries with altered …
Efficacy of an isoxazole-3-carboxamide analog of pleconaril in mouse models of Enterovirus-D68 and Coxsackie B5
TR Lane, J Fu, B Sherry, B Tarbet, BL Hurst… - Antiviral Research, 2023 - Elsevier
Enteroviruses (EV) cause a number of life-threatening infectious diseases. EV-D68 is known
to cause respiratory illness in children that can lead to acute flaccid myelitis. Coxsackievirus …
to cause respiratory illness in children that can lead to acute flaccid myelitis. Coxsackievirus …
[HTML][HTML] Targeting Human Proteins for Antiviral Drug Discovery and Repurposing Efforts: A Focus on Protein Kinases
Despite the great technological and medical advances in fighting viral diseases, new
therapies for most of them are still lacking, and existing antivirals suffer from major limitations …
therapies for most of them are still lacking, and existing antivirals suffer from major limitations …
[HTML][HTML] Identification of SARS-CoV-2 Main Protease Inhibitors Using Chemical Similarity Analysis Combined with Machine Learning
KE Juárez-Mercado, MA Gómez-Hernández… - Pharmaceuticals, 2024 - mdpi.com
SARS-CoV-2 Main Protease (Mpro) is an enzyme that cleaves viral polyproteins translated
from the viral genome, which is critical for viral replication. Mpro is a target for anti-SARS …
from the viral genome, which is critical for viral replication. Mpro is a target for anti-SARS …
Low-Dose Interferon I and III-Based Nasal Sprays: A Good-Looking COVID-19 Vaccine Candidate and a Therapy of the Future?
TN Carp, M Metoudi, B Brown, V Ojha - 2023 - preprints.org
The SARS–CoV-2 infection has caused both acute and chronic COVID–19 disease during
the recent pandemic with emerging more transmissible SARS–CoV–2 Omicron variants …
the recent pandemic with emerging more transmissible SARS–CoV–2 Omicron variants …